|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
189,490,000 |
Market
Cap: |
1.14(B) |
Last
Volume: |
2,547,018 |
Avg
Vol: |
4,440,946 |
52
Week Range: |
$4.13 - $7.98 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : 16.9 |
Insider 6 Months : 16.9 |
Insider 3/6 Months : 32.4 |
|
Guru Rank Number : 455 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile BioCryst Pharmaceuticals is a commercial-stage biotechnology company that discovers oral, small-molecule medicines. Co. focuses on oral treatments for rare diseases. Co.'s drug/drug candidates include: ORLADEYO (berotralstat), an oral serine protease inhibitor targeting kallikrein that is being developed for the prevention of Hereditary Angioedema attacks; BCX9930, an oral factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors for the treatment of fibrodysplasia ossificans progressive; and RAPIVAB® (peramivir injection), an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) ![](../../images/information.jpg) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
183,601 |
183,601 |
183,601 |
183,601 |
Total Buy Value |
$1,048,338 |
$1,048,338 |
$1,048,338 |
$1,048,338 |
Total People Bought |
10 |
10 |
10 |
10 |
Total Buy Transactions |
10 |
10 |
10 |
10 |
Total Shares Sold |
11,387 |
11,387 |
11,387 |
506,586 |
Total Sell Value |
$69,059 |
$69,059 |
$69,059 |
$6,068,300 |
Total People Sold |
2 |
2 |
2 |
10 |
Total Sell Transactions |
2 |
2 |
2 |
16 |
End Date |
2024-03-21 |
2023-12-19 |
2023-06-20 |
2022-06-20 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Jensen Peder |
Director |
|
2012-06-05 |
4 |
B |
$3.18 |
$63,680 |
D/D |
20,000 |
40,000 |
2.39 |
- |
|
Staab Thomas R Ii |
Senior Vice President and CFO |
|
2012-03-15 |
4 |
D |
$5.23 |
$21,767 |
D/D |
(4,162) |
37,124 |
|
- |
|
Staab Thomas R Ii |
Senior Vice President and CFO |
|
2012-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
11,989 |
41,286 |
|
- |
|
Lowrey Robert S |
Controller, PAO |
|
2012-03-15 |
4 |
D |
$5.23 |
$14,048 |
D/D |
(2,686) |
9,766 |
|
- |
|
Lowrey Robert S |
Controller, PAO |
|
2012-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
7,327 |
12,452 |
|
- |
|
Mccullough David |
VP |
|
2012-03-15 |
4 |
D |
$5.23 |
$27,756 |
D/D |
(5,307) |
24,124 |
|
- |
|
Mccullough David |
VP |
|
2012-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
15,505 |
29,431 |
|
- |
|
Babu Yarlagadda S |
VP Drug Discovery |
|
2012-03-15 |
4 |
D |
$5.23 |
$35,941 |
D/D |
(6,872) |
139,935 |
|
- |
|
Babu Yarlagadda S |
VP Drug Discovery |
|
2012-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
21,038 |
146,807 |
|
- |
|
Sheridan William P |
SR VP - CMO |
|
2012-03-15 |
4 |
D |
$5.23 |
$39,450 |
D/D |
(7,543) |
44,656 |
|
- |
|
Sheridan William P |
SR VP - CMO |
|
2012-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
22,869 |
52,199 |
|
- |
|
Sanders Charles A |
Director |
|
2012-03-13 |
4 |
B |
$5.22 |
$10,430 |
D/D |
2,000 |
7,000 |
2.39 |
- |
|
Stonehouse Jon P |
President & CEO |
|
2012-03-02 |
4 |
S |
$4.78 |
$13,006 |
D/D |
(2,721) |
239,384 |
|
- |
|
Sheridan William P |
SR VP - CMO |
|
2012-03-02 |
4 |
S |
$4.78 |
$4,570 |
D/D |
(956) |
29,330 |
|
- |
|
Mccullough David |
VP |
|
2012-03-02 |
4 |
S |
$4.78 |
$2,744 |
D/D |
(574) |
13,926 |
|
- |
|
Babu Yarlagadda S |
VP Drug Discovery |
|
2012-03-02 |
4 |
S |
$4.78 |
$4,001 |
D/D |
(837) |
125,769 |
|
- |
|
Stonehouse Jon P |
President & CEO |
|
2012-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
33,253 |
242,105 |
|
- |
|
Staab Thomas R Ii |
Senior Vice President and CFO |
|
2012-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
5,600 |
30,600 |
|
- |
|
Sheridan William P |
SR VP - CMO |
|
2012-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
8,500 |
30,286 |
|
- |
|
Mccullough David |
VP |
|
2012-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
8,500 |
14,500 |
|
- |
|
Babu Yarlagadda S |
VP Drug Discovery |
|
2012-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
11,200 |
126,606 |
|
- |
|
Babu Yarlagadda S |
VP Drug Discovery |
|
2012-02-29 |
4 |
OE |
$0.00 |
$0 |
D/D |
53,668 |
106,406 |
|
- |
|
Babu Yarlagadda S |
VP Drug Discovery |
|
2012-02-22 |
4 |
S |
$4.22 |
$130,449 |
D/D |
(30,912) |
52,738 |
|
- |
|
Babu Yarlagadda S |
VP Drug Discovery |
|
2012-02-22 |
4 |
OE |
$1.04 |
$36,781 |
D/D |
30,912 |
83,650 |
|
- |
|
Hutson Nancy J |
Director |
|
2012-01-20 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
5,891 |
|
- |
|
754 Records found
|
|
Page 23 of 31 |
|
|